Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.33 |
| ▸ | NOS1 | P29475 | 3/20 | 0.33 |
| ▸ | NOS2 | P35228 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3963226 | 1.00 | NOS3 (0.33) | NOS3NOS1NOS2CYP2C9ALDH1A1 | |
| Sulfuric Acid SCHEMBL5870480 | 0.88 | CYP2C9 (0.34) | CYP2C9ALDH1A1LMNAMAPT | |
| Sulfuric Acid SCHEMBL5870476 | 0.88 | CYP2C9 (0.34) | CYP2C9ALDH1A1LMNAMAPT | |
| Sulfuric Acid SCHEMBL3965231 | 0.88 | CYP2C9 (0.34) | CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL5870459 | 0.86 | CYP1A2 (0.46) | NOS1NOS2CYP2C9LMNAMAPT | |
| SCHEMBL31351926 | 0.84 | NOS3 (0.32) | NOS3NOS1NOS2CYP2C9ALDH1A1 | |
| SCHEMBL26554633 | 0.83 | SPHK1 (0.41) | CYP2C9ALDH1A1LMNAMEN1MAPK1 | |
| SCHEMBL3936529 | 0.82 | NOS1 (0.35) | NOS3NOS1NOS2CYP2C9LMNA | |
| SCHEMBL12494281 | 0.82 | NOS1 (0.35) | NOS3NOS1NOS2CYP2C9LMNA | |
| SCHEMBL27767042 | 0.82 | LMNA (0.32) | NOS3NOS1NOS2CYP2C9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119320326-B | Method for preparing lignin-based aliphatic cyclic diamine by hydroamination of lignin-based aromatic diphenol | 南京工业大学 | 2025-03-14 | — | — | CN | disclosed |
| CN-119320326-A | Method for preparing lignin-based aliphatic cyclic diamine by hydroamination of lignin-based aromatic diphenol | 南京工业大学 | 2025-01-17 | — | — | CN | disclosed |
| EP-1517911-B1 | TUMOUR-INHIBITING PLATINUM (II) OXALATE COMPLEXES | KEPPLER PROF DR DR BERNHARD K (AT) | 2009-07-29 | — | — | EP | disclosed |
| EP-1517911-B1 | TUMOUR-INHIBITING PLATINUM (II) OXALATE COMPLEXES | KEPPLER PROF DR DR BERNHARD K (AT) | 2009-07-29 | — | — | EP | disclosed |
| US-7057059-B2 | Tumor-inhibiting platinum (II) oxalate complexes | FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH (DE) | 2006-06-06 | — | — | US | disclosed |
| US-20050143455-A1 | Tumor-inhibiting platinum (II) oxalate complexes | FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH | 2005-06-30 | — | — | US | disclosed |
| EP-1517911-A1 | TUMOUR-INHIBITING PLATINUM (II) OXALATE COMPLEXES | Faustus Forschungs Cie. Translational Cancer Research GmbH (DE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2003106469-A1 | TUMOUR-INHIBITING PLATINUM (II) OXALATE COMPLEXES | FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH (DE) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143455-A1 | Tumor-inhibiting platinum (II) oxalate complexes | OXGR1, OAT, OXA1L | NOS3 852/4885NOS1 1362/4885NOS2 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.